Simvastatin lowers cholesterol levels by inhibiting HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This enzyme is responsible for converting HMG-CoA to mevalonate, an early step in the cholesterol production pathway. By blocking this enzyme, simvastatin reduces the liver’s ability to produce cholesterol.
Impact on LDL and HDL Cholesterol
This reduction in cholesterol production leads to a decrease in low-density lipoprotein (LDL) cholesterol, often referred to as “bad” cholesterol. Simultaneously, simvastatin may slightly increase high-density lipoprotein (HDL) cholesterol, or “good” cholesterol. This improved lipid profile contributes to a reduced risk of cardiovascular events.
Beyond Cholesterol Reduction
Simvastatin’s effects extend beyond cholesterol reduction. It also impacts other aspects of cardiovascular health, including reducing inflammation and improving the stability of plaque in arteries. These pleiotropic effects further contribute to its overall benefit in preventing heart disease.
